Sanofi exercises option under Nanobody deal with Ablynx

Sanofi (Euronext:SAN; NYSE:SNY) exercised an option under a July 2017 deal with Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) to receive exclusive global rights to develop and commercialize two multi-specific Nanobodies to treat immune mediated inflammatory diseases. Nanobodies are therapeutic proteins based on a single-domain antibody fragment...